Home  >  Products  >  Phyto Pain

Tetra invests significant time and capital into a continuous and sustainable pipe line of products based on patient needs and driven by scientific R&D:

Marketing Appl
Advanced Cancer Pain
Learn More
Chemotherapy Induced (Nausea & Vomiting)
Learn More
PPP002 - Dronabinol XL
Chronic Pain
Learn More
PPP002 - Dronabinol XL
Treatment for Ocular Pain & Inflammation
Learn More
Topical Cream for treatment of Neuropathic Pain
Learn More
Oral Capsules of Cannabis Oil For Treatment of Chronic Pain
Learn More

PPP001 – Dried Cannabis Prescription Drug

  • First smokable marijuana for advanced cancer pain
  • Successfully Completed Phase I – Preparing launch Phase III clinical trial Q4/17
  • Market Potential USA: 4M cancer patients & pain market $5 billion
  • Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001.

Press release September 18th 2017 - Tetra getting ready to file a CTA to initiate phase 3 clinical trial on terminal cancer patients

Press Release June 7th, 2017 – PPP001 Phase 1 results

Press Release April 19, 2017 – Tetra & Aphria have joint release

PPP002 – Dronabinol XL – Sustained Release of THC

  • Co-Development with acquisition of technology if successful Phase II in patients – Wafer buccally absorbed
  • For patients suffering chronic pain and cancer chemotherapy from nausea and vomiting
  • Advantage over approved synthetic THC:
    • Potential for significant reduction of side effects in patients and stability at room temperature
  • Both Veterinary & human indications -U.S. cancer pain market $5 billion in 2018
  • Partnership with IntelGenx Corp.

Press release April 3, 2017 – Definitive agreement with IntelGenx

PPP003 - Ocular Pain & Inflammation – Pure CBD

  • Cannabinoid based eye drops
  • Pre-clinical proof of concept completed
  • Nonclinical safety testing phase
  • First indication: Ocular pain & inflammation
  • Market Potential USA: $3 billion includes post-op inflammation, allergic conjunctivitis
  • Partnership with Panag Pharma Inc.

Press release May 23, 2017 – Definitive Agreement with Panag

PPP004 - Topical Cream – Pure THC

  • Pure THC topical cream – indicated for general neuropathic cream
  • Cannabinoid cream for the treatment of neuropathic pain
  • Market Potential USA: $2.5 billion in 2014, over the counter sales of topical analgesics according to IMS
  • Partnership with Panag Pharma Inc.

Press release May 23, 2017 – Definitive Agreement with Panag